Original Research
Accepted on 04 Nov 2025
SAFE-CGRP Study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials
in Headache and Neurogenic Pain